Delphinus Medical Technologies Company
.jpg)
Delphinus Medical Technologies develops, commercializes, and services breast cancer screening solutions to hospitals and imaging clinics. Delphinus is striving for a better breast imaging experience for women.
The standard for breast cancer screening in the United States is mammography, yet average mammography compliance in this country is just over fifty percent. In a study from Stanford University Cancer Institute, one-third of respondents were simply not interested in having mammography, possibly due to confusion over the effectiveness of it particularly for women with dense breasts, the debate regarding age-based imaging, fear of it being painful, and the radiation exposure inherent with the exam. SoftVue™ was invented to address these problems. SoftVue™ is PMA approved by the FDA indicated for dense breast cancer screening as an adjunct to mammography.
The standard for breast cancer screening in the United States is mammography, yet average mammography compliance in this country is just over fifty percent. In a study from Stanford University Cancer Institute, one-third of respondents were simply not interested in having mammography, possibly due to confusion over the effectiveness of it particularly for women with dense breasts, the debate regarding age-based imaging, fear of it being painful, and the radiation exposure inherent with the exam. SoftVue™ was invented to address these problems. SoftVue™ is PMA approved by the FDA indicated for dense breast cancer screening as an adjunct to mammography.
Industry:
General Healthcare
Headquarters:
Novi, Michigan, United States
Founded Date:
01-01-2010
Employees Number:
11-50
Funding Status:
Late Stage Venture
Investors Number:
8
Total Funding:
$97,136,010
Estimated Revenue:
$1M to $10M
Last Funding Date:
2022-09-13
Last Funding Type:
Series D
Register and Claim Ownership